Emerging drugs for the treatment of light chain amyloidosis

References

• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583–596.
   PubMed Web of Science ®Google Scholar
• Riek R, Eisenberg DS. The activities of amyloids from a structural perspective. Nature. 2016;539(7628):227–235.
   PubMed Web of Science ®Google Scholar
• Merlini G. AL amyloidosis: from molecular mechanisms to targeted therapies. Hematology Am Soc Hematol Educ Program. 2017;2017(1):1–12.
   PubMed Web of Science ®Google Scholar
• Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006;108(8):2520–2530.
   PubMed Web of Science ®Google Scholar
• Blancas-Mejía LM, Ramirez-Alvarado M. Systemic amyloidoses. Annu Rev Biochem. 2013;82(1):745–774.
   PubMedGoogle Scholar
• Kourelis TV, Dasari S, Theis JD, et al. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. Blood. 2017;129(3):299–306.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol. 2020;95(7):848–860.
   Web of Science ®Google Scholar
• Kyle RA, Larson DR, Kurtin PJ, et al. Incidence of AL amyloidosis in olmsted county, Minnesota, 1990 through 2015. Mayo Clin Proc. 2019;94(3):465–471.
   PubMed Web of Science ®Google Scholar
• Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and survival trends in amyloidosis, 1987–2019. N Engl J Med. 2020;382(16):1567–1568.
   PubMed Web of Science ®Google Scholar
• Quock TP, Yan T, Chang E, et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018;2(10):1046–1053.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Gertz MA, Kumar SK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129(15):2111–2119. .
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336(17):1202–1207.
   PubMed Web of Science ®Google Scholar
• Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood. 2007;110(2):787–788.
   PubMed Web of Science ®Google Scholar
• Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357(11):1083–1093.
   PubMed Web of Science ®Google Scholar
• Sidiqi MH, Aljama MA, Buadi FK, et al. Stem cell transplantation for light chain amyloidosis: decreased early mortality over time. J Clin Oncol. 2018;36(13):1323–1329.
   PubMed Web of Science ®Google Scholar
• D’Souza A, Dispenzieri A, Wirk B, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a center for international blood and marrow transplant research study. J Clin Oncol. 2015;33(32):3741–3749.
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391–4394.
   PubMed Web of Science ®Google Scholar
• Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612–615.
   PubMed Web of Science ®Google Scholar
• Manwani R, Cohen O, Sharpley F, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271–2280. .
   PubMed Web of Science ®Google Scholar
• Cornell RF, Hari P, Goodman S, et al. Bortezomib induction prior to autologous hematopoietic cell transplantation (AHCT) for newly diagnosed light chain amyloidosis (AL): A study of 426 patients. Am Soc Clin Oncol. 2020;38(15_suppl):8515.
   Web of Science ®Google Scholar
• Amyloidosis treatment market size, share & trends analysis report by treatment (stem cell transplant, chemotherapy, supportive care, surgery, targeted therapy), By Country, And Segment Forecasts, 2018–2025; 2020.
   Google Scholar
• Palladini G, Milani P, Foli A, et al. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood. 2018;131(5):525–532.
   PubMed Web of Science ®Google Scholar
• Hwa YL, Warsame R, Gertz MA, et al. Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. Blood. 2017;130(13):1578–1584.
   PubMed Web of Science ®Google Scholar
• Wilcock P, Webster R. The multiple myeloma drug market. Nat Rev Drug Discov. 2019;18(8):579–580.
   PubMed Web of Science ®Google Scholar
• Sidana S, Sidiqi MH, Dispenzieri A, et al. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. Am J Hematol. 2019;94(9):1020–1026.
   PubMed Web of Science ®Google Scholar
• Popkova T, Hajek R, Jelinek T. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits. Br J Haematol. 2020;189(2):228–238.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5)::597–605.
   Web of Science ®Google Scholar
• Dispenzieri A, Kastritis E, Wechalekar AD, et al. Primary results from the phase 3 tourmaline-AL1 trial of ixazomib-dexamethasone versus physician’s choice of therapy in patients (pts) with relapsed/refractory primary systemic AL amyloidosis (RRAL). Blood. 2019;134(Supplement_1):139.
   Google Scholar
• Kastritis E, Dispenzieri A, Wechalekar AD. Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial. ASCO virtual scientific program. Am Soc Clin Oncol. 2020;38(15_suppl):8546.
   PubMed Web of Science ®Google Scholar
• Cohen OC, Sharpley F, Gillmore JD, et al. Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis. Br J Haematol. 2020;189(4):643–649.
   PubMed Web of Science ®Google Scholar
• Waxman AJ, Clasen S, Hwang WT, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018;4(3):e174519.
   PubMed Web of Science ®Google Scholar
• Ball S, Behera TR, Anwer F, et al. Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials. Ann Hematol. 2020;99(6):1265–1271.
   PubMed Web of Science ®Google Scholar
• Facon T, Lee JH, Moreau P, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019;133(18):1953–1963.
   PubMed Web of Science ®Google Scholar
• Kumar S, Jacobus SJ, Cohen AD. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): results of ENDURANCE (E1A11) phase III trial. ASCO Virtual Scientific Program. Am Soc Clin Oncol. 2020;38(18_suppl):LBA3-LBA3.
   Web of Science ®Google Scholar
• Cohen AD, Landau H, Scott EC, et al. Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis. Blood. 2016;128(22):645.
   Web of Science ®Google Scholar
• Manwani R, Mahmood S, Sachchithanantham S, et al. Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. Br J Haematol. 2019;187(5):638–641.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007;109(2):465–470.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Gavriatopoulou M, Roussou M, et al. Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. Amyloid. 2018;25(4):234–241.
   PubMed Web of Science ®Google Scholar
• Mahmood S, Venner CP, Sachchithanantham S, et al. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. Br J Haematol. 2014;166(6):842–848.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Shelton AC, Lo S, et al. Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood. 2016;128(8):1059–1062.
   PubMed Web of Science ®Google Scholar
• Palladini G, Milani P, Foli A, et al. A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood. 2017;129(15):2120–2123.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Buadi F, Laumann K, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012;119(23):5397–5404.
   PubMed Web of Science ®Google Scholar
• Milani P, Sharpley F, Schönland SO, et al. Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. Amyloid. 2020;1–6. 10.1080/13506129.2020.1767566
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–1848.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311–321.
   PubMed Web of Science ®Google Scholar
• Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. 2014;124(21):3474.
   Web of Science ®Google Scholar
• Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–1219.
   PubMed Web of Science ®Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551–1560.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):37–44.
   PubMed Web of Science ®Google Scholar
• Sher T, Fenton B, Akhtar A, et al. First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis. Blood. 2016;128(15):1987–1989.
   PubMed Web of Science ®Google Scholar
• Kaufman GP, Schrier SL, Lafayette RA, et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130(7):900–902.
   PubMed Web of Science ®Google Scholar
• Khouri J, Kin A, Thapa B, et al. Daratumumab proves safe and highly effective in AL amyloidosis. Br J Haematol. 2019;185(2):342–344.
   PubMed Web of Science ®Google Scholar
• Abeykoon JP, Zanwar S, Dispenzieri A, et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia. 2019;33:531–536.
   PubMed Web of Science ®Google Scholar
• Lecumberri R, Krsnik I, Askari E, et al. Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature. Amyloid. 2020; Sep;27(3):163–167.
   PubMed Web of Science ®Google Scholar
• Milani P, Fazio F, Basset M, et al. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate. Am J Hematol. 2020;95(8):900–905.
   PubMed Web of Science ®Google Scholar
• Chung A, Kaufman GP, Sidana S, et al. Organ responses with daratumumab therapy in previously treated AL amyloidosis. Blood Adv. 2020;4:458–466.
   PubMed Web of Science ®Google Scholar
• Kimmich CR, Terzer T, Benner A, et al. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. Blood. 2020;135(18):1517–1530. .
   PubMed Web of Science ®Google Scholar
• Roussel M, Merlini G, Chevret S, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. Blood. 2020;135(18):1531–1540.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Sarosiek S, Schulman A, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood. 2020;135(18):1541–1547.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Dispenzieri A, Leung N, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. 2018;32(10):2240–2249.
   PubMed Web of Science ®Google Scholar
• Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136(1):71–80.
   PubMed Web of Science ®Google Scholar
• Efstathios Kastritis GP, Minnema MC, Wechalekar AD, et al. Comenzo: subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone (cybord) in patients with newly diagnosed light chain (AL) amyloidosis: primary results from the phase 3 andromeda study. In EHA25; 2020.
   Google Scholar
• Moreno L, Perez C, Zabaleta A, et al. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res. 2019;25(10):3176–3187.
   PubMed Web of Science ®Google Scholar
• Martin T, Baz R, Benson DM, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017;129(25):3294–3303.
   PubMed Web of Science ®Google Scholar
• Premkumar V, Lentzsch S, Bhutani D. Single arm, prospective, open-label phase II trial to evaluate the efficacy of isatuximab in patients with monoclonal gammopathy of renal significance. Blood. 2019;134(Supplement_1):3161.
   Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120(3):552–559.
   PubMed Web of Science ®Google Scholar
• Li L, Tong W, Lau M, et al. Preclinical development of an anti-CD38 antibody-drug conjugate for treatment of hematological malignancies. Blood. 2019;134(Supplement_1):5621.
   Google Scholar
• Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–221.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26(9):1324–1337.
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120.
   PubMed Web of Science ®Google Scholar
• Bodet L, Gomez-Bougie P, Touzeau C, et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood. 2011;118(14):3901–3910.
   PubMed Web of Science ®Google Scholar
• Touzeau C, Ryan J, Guerriero J, et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016;30(3):761–764.
   PubMed Web of Science ®Google Scholar
• Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130(22):2401–2409.
   PubMed Web of Science ®Google Scholar
• Kumar S, Harrison SJ, Cavo M, et al. A phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leukemia. 2019;19(10):e31.
   Web of Science ®Google Scholar
• Harrison S, Cavo M, De La Rubia J, et al. T(11;14) and high BCL2 expression are predictive biomarkers of response to venetoclax in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma: biomarker analyses from the phase 3 bellini study. Blood. 2019;134(Supplement_1):142.
   Google Scholar
• Hayman SR, Bailey RJ, Jalal SM, et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood. 2001;98(7):2266–2268.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Dispenzieri A, Kumar SK, et al. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia. 2017;31(7):1562–1569.
   PubMed Web of Science ®Google Scholar
• Leung N, Thome SD, Dispenzieri A. Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone. Haematologica. 2018;103(3):e135–e137.
   PubMed Web of Science ®Google Scholar
• Yip PL, Lau JSM, Lam CP. Venetoclax monotherapy induced rapid and sustained response in a frail patient with refractory AL amyloidosis: less is more? Int J Hematol. 2020;112(2):234–237.
   PubMed Web of Science ®Google Scholar
• Gran C, Borg Bruchfeld J, Ellin F, et al. Rapid complete response to single-agent Bcl-2 inhibitor venetoclax in a heart-transplanted patient with triple refractory immunoglobulin light-chain amyloidosis. Acta Haematol. 2020;1–4. Doi:10.1159/000504355
   PubMed Web of Science ®Google Scholar
• Premkumar V, Comenzo R, Lentzsch S. Venetoclax in immunoglobulin light chain amyloidosis: is this the beginning or the end? Clin Lymphoma Myeloma Leuk. 2019;19(10):686–688.
   PubMed Web of Science ®Google Scholar
• Basali D, Chakraborty R, Rybicki L, et al. Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma. Br J Haematol. 2020;189(6):1136–1140.
   PubMed Web of Science ®Google Scholar
• Sidiqi MH, Al Saleh AS, Leung N, et al. Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer J. 2020;10(5):55.
   PubMed Web of Science ®Google Scholar
• Milani P, Schönland S, Merlini G, et al. Treatment of AL amyloidosis with bendamustine: a study of 122 patients. Blood. 2018;132(18):1988–1991.
   PubMed Web of Science ®Google Scholar
• Lentzsch S, Lagos GG, Comenzo RL, et al. Bendamustine with dexamethasone in relapsed/refractory systemic light-chain amyloidosis: results of a phase II study. J Clin Oncol. 2020;38(13):1455–1462.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Rummel MJ. Bendamustine: rebirth of an Old Drug. J Clin Oncol. 2009;27(9):1492–1501.
   PubMed Web of Science ®Google Scholar
• Sarosiek S, Sloan JM, Quillen K, et al. Safety and efficacy of propylene glycol-free melphalan (evomela) in patients with AL amyloidosis undergoing autologous stem cell transplantation: preliminary results of a phase II study. Blood. 2019;134(Supplement_1):4578.
   Google Scholar
• Flanagan K, Majumder MM, Kumari R, et al. In vitro and invivo activity of melflufen in amyloidosis. Blood. 2019;134(Supplement_1):3100.
   Google Scholar
• Sidana S, Larson DP, Greipp PT, et al. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia. 2020;34(5):1373–1382.
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Novak AJ, Ansell SM, et al. First report of MYD88 L265P somatic mutation in IgM-associated light-chain amyloidosis. Blood. 2016;127(23)::2936–2938.
   PubMed Web of Science ®Google Scholar
• Basset M, Defrancesco I, Milani P, et al. Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis. Blood. 2020;135(4):293–296.
   PubMed Web of Science ®Google Scholar
• Abe M, Goto T, Kennel SJ, et al. Production and immunodiagnostic applications of antihuman light chain monoclonal antibodies. Am J Clin Pathol. 1993;100(1):67–74.
   PubMed Web of Science ®Google Scholar
• Hrncic R, Wall J, Wolfenbarger DA, et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol. 2000;157(4):1239–1246.
   PubMed Web of Science ®Google Scholar
• Solomon A, Weiss DT, Wall JS. Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4. Clin Cancer Res. 2003;9(10 Pt 2):3831s–3838s.
   PubMed Web of Science ®Google Scholar
• Edwards CV, Gould J, Langer AL, et al. Final analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with relapsed or refractory AL amyloidosis. Blood. 2017;130:509.
   Google Scholar
• Bhutani D, Leng S, Eisenberger A, et al. Improvement in Global Longitudinal Strain (GLS) correlates with NT-probnp response in patients with cardiac amyloidosis treated on a phase 1b study of anti-amyloid Mab Cael-101. Blood. 2018;132(Supplement 1):958.
   Google Scholar
• Wall JS, Kennel SJ, Williams A, et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One. 2012;7(12):e52686.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Landau H, Comenzo RL, et al. First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol. 2016;34(10):1097–1103.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Cohen AD, Comenzo RL, et al. Results of the phase 3 VITAL study of NEOD001 (Birtamimab) plus standard of care in patients with light chain (AL) amyloidosis suggest survival benefit for mayo stage IV patients. Blood. 2019;134(Supplement_1):3166.
   Google Scholar
• Prothena: Prothena Discontinues Development Of NEOD001 For AL Amyloidosis. Edited by; 2018.
   Google Scholar
• Varga C, Dispenzieri A, Gertz MA, et al. Rain (renal AL amyloid involvement and NEOD001): a multicenter, randomized, phase 2b study of NEOD001 in previously treated subjects with systemic AL amyloidosis and persistent renal involvement. Blood. 2017;130:5437.
   Web of Science ®Google Scholar
• Varga C, Lentzsch S, Comenzo RL. Beyond NEOD001 for systemic light-chain amyloidosis. Blood. 2018;132(18):1992–1993.
   PubMed Web of Science ®Google Scholar
• Bhutani D, Leng S, Lentzsch S. Fibril-directed therapies in systemic light chain AL amyloidosis. Clin Lymphoma Myeloma Leuk. 2019;19(9):555–559.
   PubMed Web of Science ®Google Scholar
• Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468(7320):93–97.
   PubMed Web of Science ®Google Scholar
• Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med. 2015;373(12):1106–1114.
   PubMed Web of Science ®Google Scholar
• Richards DB, Cookson LM, Barton SV, et al. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Sci Transl Med. 2018 Jan 3;10(422):eaan3128.
   Web of Science ®Google Scholar
• Ward JE, Ren R, Toraldo G, et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood. 2011;118(25):6610–6617.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer J. 2017;7(3):e546.
   PubMedGoogle Scholar
• D’Souza A, Szabo A, Flynn KE, et al. Adjuvant doxycycline to enhance anti-amyloid effects: results from the dual phase 2 trial. E Clin Med. 2020;23:100361.
   Google Scholar
• Palhano FL, Lee J, Grimster NP, et al. Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. J Am Chem Soc. 2013;135(20):7503–7510.
   PubMed Web of Science ®Google Scholar
• Hegenbart U: EGCG treatment in patients with cardiac AL amyloidosis: first results of a randomized and placebo-controlled clinical trial of GERAMY. In International Symposium on Amyloidosis 2018. Kuamamoto, Japan; 2018.
   Google Scholar
• Kumar S, Harrison SJ, Cavo M, et al. Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. ASCO Virtual Scientific Program,Edited by Shaji Kumar SJHMCJdLRRPCGVHHSKSIKFGGMEPW-J, Mayo Clinic RMN, Peter MacCallum Cancer C, Royal Melbourne Hospital MA, Ser, xE, gnoli Institute of Hematology BUSoMBI, Hematology Service Hospital Dr P, School of M, Dentistry CUoVVS, et al.: American Society of Clinical Oncology: 2020.
   Google Scholar